ArticleWorld journal of gastroenterology2005
Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.
Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- The siRNA silencing of DcR3 expression induces Fas ligand-mediated apoptosis in HepG2 cells.Experimental and therapeutic medicine · 2018Article
- DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC.Oncotarget · 2016Article
- Knockdown of Decoy Receptor 3 Impairs Growth and Invasiveness of Hepatocellular Carcinoma Cell Line of HepG2.Chinese medical journal · 2016Article
- Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.The Journal of pathology · 2016Article
- Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease.Canadian journal of gastroenterology & hepatology · 2016Article
- Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.International journal of clinical and experimental medicine · 2014Article
- Article
- The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.Immunological reviews · 2011Review
- Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.Experimental and therapeutic medicine · 2011Article
- Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients.Upsala journal of medical sciences · 2010Article
- Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.Leukemia · 2009Article
- Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.British journal of pharmacology · 2009Article
- Significance of increased expression of decoy receptor 3 in chronic liver disease.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2009Article
- Decoy receptor 3 is a prognostic factor in renal cell cancer.Neoplasia (New York, N.Y.) · 2008Article
- Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter.Journal of virology · 2007Article
- The Role of Decoy Receptor DcR3 in Gastrointestinal Malignancy.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize the expression and genomic amplification of decoy receptor 3 (DcR3) in hepatocellular carcinoma (HCC) and to evaluate the role of DcR3 in apoptosis.
methodsWe examined 48 cases of HCC for DcR3 expression by RT-PCR and DcR3 gene amplification by quantitative genomic PCR. DcR3 protein was detected by immunohistochemistry. Terminal deoxynucleotidyl transferase-mediated dUTP digoxigenin nick and labeling (TUNEL) was used to identify the apoptosis cells in tissues. Primary hepatoma cell culture and MTT test were used to evaluate the protection against FasL- and chemical-induced apoptosis by DcR3 expression.
resultsDcR3 mRNA overexpression was detected in 60% HCC (29/48) patients. The occurrence of HCC was not associated with amplification of the gene. One sample base substitution was found in three sites as sequence in Genbank. The expression of DcR3 in HCC was the associatied with the apoptotic index (0.067+/-0.04 vs 0.209+/-0.12, P<0.01), size of mass, stage and infiltration or metastasis (41.2% vs 71.0%, 40% vs 75%, 51.8% vs 84.6%, P<0.05). DcR3 expression could be protect hepatoma cells against apoptosis induced by FasL, but not by chemicals.
conclusionThese data suggest that in addition to gene amplification there may be another mechanism underlying DcR3 overexpression. The effect of overexpression of DcR3 on the apoptosis of cancer cells may have direct therapeutic implications for the management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.